Wave Life Sciences announces data from Phase 2 FORWARD-53 trial of WVE-N531
Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being ...
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.
One Stop Systems announces data from FORWARD-53 trial of WVE-N531
Wave Life Sciences announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being ...
Nintendo Switch 2 multi-phase launch plan potentially leaked
The Nintendo Direct focused on the Nintendo Switch 2 is just a week away, but the company’s launch plans might have leaked a ...
What is Model Context Protocol (MCP) and Why Does it Matter?
Learn why MCP is the future of AI integration, offering a standardized framework to unlock advanced applications and ...
Fierce Biotech6d
MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data
MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...
STAT1d
Wave to submit Duchenne drug for approval after Phase 2 success
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
Science X Network1d
Chinese Meridian Project phase II transforms space environment monitoring with global impact
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Healio2d
Phase 3 COAST trial of wet AMD combination therapy misses primary endpoint
The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...